GlassScriptPhysician profile
Rodney B Trimble
NPI 1922056597
$4,681.53
in general payments reported to CMS, 2019-2025
27 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $296 · 2021: $353 · 2022: $320 · 2023: $432 · 2024: $986 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,004.20 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $630.38 | 2019-2025 | |
| Janssen Biotech, INC. | $526.86 | 2019-2021 | |
| Theratechnologies INC. | $511.86 | 2021-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $431.12 | 2019-2025 | Pifeltro, Delstrigo |
| Takeda Pharmaceuticals U.S.A., INC. | $199.09 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $184.34 | 2019-2024 | Spravato |
| Novo Nordisk INC | $181.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Napo Pharmaceuticals INC | $139.36 | 2023-2025 | Mytesi |
| Emd Serono, INC. | $118.65 | 2021-2025 | |
| Janssen Products, LP | $99.95 | 2021 | |
| Abbvie INC. | $98.43 | 2019 | |
| Indivior INC. | $69.59 | 2019-2025 | Sublocade |
| Amgen INC. | $66.70 | 2019-2025 | Otezla, Repatha |
| Corium, LLC | $62.66 | 2024 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.80 | 2023-2025 | Mounjaro |
| Antares Pharma, INC. | $56.38 | 2019-2024 | Xyosted |
| Madrigal Pharmaceuticals | $51.73 | 2025 | Rezdiffra |
| Alkermes, INC. | $43.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $31.35 | 2023 | Farxiga |
| Pfizer INC. | $21.82 | 2025 | |
| Medtronic, INC. | $17.30 | 2025 | Inceptiv |
| Halozyme INC | $16.45 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.11 | 2019 | |
| Allergan, INC. | $14.90 | 2020 | |
| Shire North American Group INC | $14.41 | 2019 | |
| Amarin Pharma, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Trimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.